142 related articles for article (PubMed ID: 32186609)
1. [H3K27 positive diffuse midline glioma. Report of one case].
Araneda P; Sujima E; Paredes-Manzo P; Vallejo R; Valdivia F; Sinning M; Gallegos M; Fuller G
Rev Med Chil; 2019 Nov; 147(11):1487-1490. PubMed ID: 32186609
[No Abstract] [Full Text] [Related]
2. Significance of H3K27M Mutation in "Nonmidline" High-Grade Gliomas of Cerebral Hemispheres.
La Rocca G; Sabatino G; Altieri R; Signorelli F; Ricciardi L; Gessi M; Della Pepa GM
World Neurosurg; 2019 Nov; 131():174-176. PubMed ID: 31415896
[TBL] [Abstract][Full Text] [Related]
3. K27M midline gliomas display malignant progression by imaging and histology.
Vettermann FJ; Neumann JE; Suchorska B; Bartenstein P; Giese A; Dorostkar MM; Albert NL; Schüller U
Neuropathol Appl Neurobiol; 2017 Aug; 43(5):458-462. PubMed ID: 27997032
[No Abstract] [Full Text] [Related]
4. Imaging Characteristics of Pediatric Diffuse Midline Gliomas with Histone H3 K27M Mutation.
Aboian MS; Solomon DA; Felton E; Mabray MC; Villanueva-Meyer JE; Mueller S; Cha S
AJNR Am J Neuroradiol; 2017 Apr; 38(4):795-800. PubMed ID: 28183840
[TBL] [Abstract][Full Text] [Related]
5. Indolent presentation of a diffuse midline glioma, H3 K27-altered.
Damodharan S; Helgager J; Puccetti D
Childs Nerv Syst; 2023 Mar; 39(3):833-835. PubMed ID: 36094605
[TBL] [Abstract][Full Text] [Related]
6. Diffuse Midline Gliomas without the H3 K27M Mutation: Surgical Biopsy is Needed to Better our Diagnostic Understanding.
Lu VM; Raghunathan A; Schwartz JD; Daniels DJ
World Neurosurg; 2020 May; 137():472-473. PubMed ID: 32365434
[No Abstract] [Full Text] [Related]
7. Diffuse non-midline glioma with H3F3A K27M mutation: a prognostic and treatment dilemma.
López G; Oberheim Bush NA; Berger MS; Perry A; Solomon DA
Acta Neuropathol Commun; 2017 May; 5(1):38. PubMed ID: 28506301
[No Abstract] [Full Text] [Related]
8. H3K27M-mutant diffuse midline glioma presenting as synchronous lesions involving pineal and suprasellar region: A case report and literature review.
Lim JX; Leong A; Tan AP; Tan CL; Nga VDW
J Clin Neurosci; 2020 Nov; 81():144-148. PubMed ID: 33222904
[TBL] [Abstract][Full Text] [Related]
9. Slow-Growing Thalamic Glioma with Histone H3 Lysine 27-to-Methionine Mutation: 3-Year Follow-Up Before Surgical Intervention.
Chanchotisatien A; Pan J; Du Z; Qiu T; Yu J; Chu S
World Neurosurg; 2019 Jul; 127():266-268. PubMed ID: 30981797
[TBL] [Abstract][Full Text] [Related]
10. Incidence and clinicopathologic features of H3 K27M mutations in adults with radiographically-determined midline gliomas.
Schreck KC; Ranjan S; Skorupan N; Bettegowda C; Eberhart CG; Ames HM; Holdhoff M
J Neurooncol; 2019 May; 143(1):87-93. PubMed ID: 30864101
[TBL] [Abstract][Full Text] [Related]
11. Four methods to analyze H3K27M mutation in diffuse midline gliomas.
Zhao H; Fang X; Xue B
Pathol Res Pract; 2020 Sep; 216(9):153065. PubMed ID: 32825938
[TBL] [Abstract][Full Text] [Related]
12. Diffuse midline gliomas with subclonal H3F3A K27M mutation and mosaic H3.3 K27M mutant protein expression.
Lopez GY; Oberheim Bush NA; Phillips JJ; Bouffard JP; Moshel YA; Jaeckle K; Kleinschmidt-DeMasters BK; Rosenblum MK; Perry A; Solomon DA
Acta Neuropathol; 2017 Dec; 134(6):961-963. PubMed ID: 29063183
[No Abstract] [Full Text] [Related]
13. Diffuse Midline Glioma With Osseous Metastases at Diagnosis: A Case Report.
Bhatt NS; Houser K; Belongia M; Ellison DW; Foy A; Jarzembowski J; Kelly T; Maheshwari M; Suchi M; Knipstein J
J Pediatr Hematol Oncol; 2020 Oct; 42(7):e673-e676. PubMed ID: 31568066
[TBL] [Abstract][Full Text] [Related]
14. Histone H3 wild-type DIPG/DMG overexpressing EZHIP extend the spectrum diffuse midline gliomas with PRC2 inhibition beyond H3-K27M mutation.
Castel D; Kergrohen T; Tauziède-Espariat A; Mackay A; Ghermaoui S; Lechapt E; Pfister SM; Kramm CM; Boddaert N; Blauwblomme T; Puget S; Beccaria K; Jones C; Jones DTW; Varlet P; Grill J; Debily MA
Acta Neuropathol; 2020 Jun; 139(6):1109-1113. PubMed ID: 32193787
[No Abstract] [Full Text] [Related]
15. Diffuse high-grade gliomas with H3 K27M mutations carry a dismal prognosis independent of tumor location.
Karremann M; Gielen GH; Hoffmann M; Wiese M; Colditz N; Warmuth-Metz M; Bison B; Claviez A; van Vuurden DG; von Bueren AO; Gessi M; Kühnle I; Hans VH; Benesch M; Sturm D; Kortmann RD; Waha A; Pietsch T; Kramm CM
Neuro Oncol; 2018 Jan; 20(1):123-131. PubMed ID: 29016894
[TBL] [Abstract][Full Text] [Related]
16. MRI comparative study of diffuse midline glioma, H3 K27-altered and glioma in the midline without H3 K27-altered.
Zhao JP; Liu XJ; Lin HZ; Cui CX; Yue YJ; Gao S; Xu HZ
BMC Neurol; 2022 Dec; 22(1):498. PubMed ID: 36550486
[TBL] [Abstract][Full Text] [Related]
17. A case of diffuse midline glioma, H3 K27M mutant mimicking a hemispheric malignant glioma in an elderly patient.
Fujioka Y; Hata N; Hatae R; Suzuki SO; Sangatsuda Y; Nakahara Y; Mizoguchi M; Iihara K
Neuropathology; 2020 Feb; 40(1):99-103. PubMed ID: 31762138
[TBL] [Abstract][Full Text] [Related]
18. The Performance of Machine Learning for Prediction of H3K27 M Mutation in Midline Gliomas: A Systematic Review and Meta-Analysis.
Habibi MA; Aghaei F; Tajabadi Z; Mirjani MS; Minaee P; Eazi S
World Neurosurg; 2024 Jun; 186():e7-e19. PubMed ID: 37995996
[TBL] [Abstract][Full Text] [Related]
19. Extending the Neuroanatomic Territory of Diffuse Midline Glioma, K27M Mutant: Pineal Region Origin.
Gilbert AR; Zaky W; Gokden M; Fuller CE; Ocal E; Leeds NE; Fuller GN
Pediatr Neurosurg; 2018; 53(1):59-63. PubMed ID: 29131126
[TBL] [Abstract][Full Text] [Related]
20. Mutations within FGFR1 are associated with superior outcome in a series of 83 diffuse midline gliomas with H3F3A K27M mutations.
Schüller U; Iglauer P; Dorostkar MM; Mawrin C; Herms J; Giese A; Glatzel M; Neumann JE
Acta Neuropathol; 2021 Feb; 141(2):323-325. PubMed ID: 33433639
[No Abstract] [Full Text] [Related]
[Next] [New Search]
